Comment from Arnall Golden Gregory LLP

Summary: Arnall Golden Gregory LLP, representing a client, argues that intrathecal baclofen is not appropriate for bulk compounding due to significant safety risks, lack of unmet clinical need, and the availability of FDA-approved commercial products. They request that the FDA remove the substance from the interim list of substances under evaluation and formally determine it is not appropriate for the Bulk Substances List.